Author:
Reddy Kesava,Bukowski Ronald M.
Reference8 articles.
1. Final results of a phase I and pharmacokinetic study of SU11248, a novel multi-target tyrosine kinase inhibitor, in patients with advanced cancers;Raymond;Proc Am Soc Clin Oncol,2003
2. Phase I trial of SU011248, a novel tyrosine kinase inhibitor in advanced solid tumors;Rosen;Proc Am Soc Clin Oncol,2003
3. Activity of SU111248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma;Motzer;J Clin Oncol,2006
4. Sunitinib in patients with metastatic renal cell carcinoma;Motzer;JAMA,2006
5. Motzer RJ, Hutson TE, Tomczak P, et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). Presented at: The 42nd Annual Meeting of the American Society of Clinical Oncology; June 4-6, 2006; Atlanta, GA. Abstract #LBA3.
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献